Tryp Therapeutics Inc.: Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support
The agreement with Clinlogix is a key step for initiating Tryp s Phase 2a clinical trials
San Diego, California (Newsfile Corp. - May 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ( Tryp ), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryp s clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFN
TM) program.
Clinlogix has global experience with providing CRO services for the development of novel pharmaceutical products. The company will collaborate with Tryp and its clinical partners in a number of areas including medical writing, biostatistical analysis, data management, and trial monitoring.
Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Article content
San Diego, California–(Newsfile Corp. – May 10, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryp’s clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFN
TM) program.
Try refreshing your browser. Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support Back to video
Clinlogix has global experience with providing CRO services for the development of novel pharmaceutical products. The company will collaborate with Tryp and its clinical partners in a number of areas including medical writing, biostatistical analysis, data management, and trial monitoring.